--- title: "Rapt Therapeutics (NASDAQ:RAPT) Hits New 12-Month High - Here's Why" type: "News" locale: "en" url: "https://longbridge.com/en/news/274956442.md" description: "Rapt Therapeutics (NASDAQ:RAPT) reached a new 52-week high of $57.86 during trading, closing at $57.78. Analysts have downgraded the stock's ratings, with Lifesci Capital and Guggenheim changing their ratings to 'hold' and 'neutral', respectively. The stock has an average rating of 'Hold' with a consensus price target of $48.44. Rapt Therapeutics, a clinical-stage biotech firm, focuses on developing therapies for autoimmune diseases. Institutional investors own 99.09% of the stock, and the company reported a quarterly EPS of ($0.65), beating estimates." datetime: "2026-02-05T10:39:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274956442.md) - [en](https://longbridge.com/en/news/274956442.md) - [zh-HK](https://longbridge.com/zh-HK/news/274956442.md) --- # Rapt Therapeutics (NASDAQ:RAPT) Hits New 12-Month High - Here's Why Rapt Therapeutics (NASDAQ:RAPT - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $57.86 and last traded at $57.78, with a volume of 6026119 shares changing hands. The stock had previously closed at $57.75. Get **Rapt Therapeutics** alerts: ## Wall Street Analyst Weigh In A number of equities analysts have recently commented on the stock. Lifesci Capital downgraded shares of Rapt Therapeutics from an "outperform" rating to a "hold" rating in a report on Tuesday, January 20th. Guggenheim lowered shares of Rapt Therapeutics from a "buy" rating to a "neutral" rating in a research report on Tuesday, January 20th. Piper Sandler downgraded Rapt Therapeutics from an "overweight" rating to a "neutral" rating and set a $58.00 price objective on the stock. in a report on Tuesday, January 20th. Clear Str lowered Rapt Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, January 20th. Finally, Wells Fargo & Company cut Rapt Therapeutics from an "overweight" rating to an "equal weight" rating and set a $58.00 target price for the company. in a report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $48.44. **Get Our Latest Report on RAPT** ## Rapt Therapeutics Trading Up 0.1% The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -5.22 and a beta of 0.47. The firm has a fifty day moving average price of $39.64 and a 200 day moving average price of $27.34. Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.23. As a group, equities analysts predict that Rapt Therapeutics will post -2.14 EPS for the current fiscal year. ## Institutional Inflows and Outflows A number of large investors have recently made changes to their positions in the stock. Boone Capital Management LLC bought a new stake in shares of Rapt Therapeutics during the third quarter worth $20,180,000. AQR Capital Management LLC bought a new stake in Rapt Therapeutics in the 1st quarter valued at $188,000. Invesco Ltd. acquired a new position in Rapt Therapeutics in the 3rd quarter worth $3,625,000. SummitTX Capital L.P. bought a new position in Rapt Therapeutics during the 3rd quarter worth about $2,370,000. Finally, Velan Capital Investment Management LP acquired a new stake in shares of Rapt Therapeutics in the 3rd quarter valued at about $2,063,000. Institutional investors and hedge funds own 99.09% of the company's stock. ## Rapt Therapeutics Company Profile (Get Free Report) RAPT Therapeutics, Inc NASDAQ: RAPT is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company's research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies. The company's lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma. ## Featured Articles - Five stocks we like better than Rapt Therapeutics - The day the gold market broke - Buy this Gold Stock Before May 2026 - Trump Planning to Use Public Law 63-43: Prepare Now - Forget AI, This Will Be the Next Big Tech Breakthrough - What a Former CIA Agent Knows About the Coming Collapse _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Rapt Therapeutics Right Now? Before you consider Rapt Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list. While Rapt Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [RAPT.US](https://longbridge.com/en/quote/RAPT.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) ## Related News & Research - [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md) - [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md) - [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md) - [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md) - [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md)